Harmonized COVID-19 Vaccine Immune Response Data from Multiple Cohorts

This harmonized dataset contains pseudonymized data on antibody responses, infections, and vaccination status from multiple research groups within the Harmony Consortium, focusing on healthy volunteers and immunocompromised patients. It includes measurements of anti-S1, anti-N, and anti-RBD antibody titers, with limited T-cell response data from a small patient group. The dataset is accompanied by a data management plan, codebook, and harmonization templates.

Use Cases

• Analyze anti-S1, anti-N, and anti-RBD antibody titer dynamics across healthy and immunocompromised patient cohorts.
• Correlate vaccination status and prior infection history with measured antibody response levels.
• Investigate the limited T-cell response data available for a subset of patients in relation to their antibody profiles.

Strengths

• Data is harmonized from over 10 distinct research groups, including RECOVAC, COVALENT, and VACOPID.
• Includes multiple specific antibody measurements (anti-S1, anti-N, anti-RBD) per subject.
• Combines data on antibody responses, infection history, and vaccination status.

Limitations

• T-cell response data is described as limited and available only for a small group of patients.
• Access requires a formal application process and approval from a steering committee, potentially delaying use.
• The project is ongoing until March 2025, and data requests are only processed from that point onward.

Provenance

Source

Harmony Consortium, comprising research groups from UMCG, Erasmus MC, UMCU, OLVG, AUMC, and RIVM.

Collection Method

Harmonized data from multiple clinical studies on COVID-19 vaccine effects.

Freshness

Last updated on 2025-10-23.

Geography

Netherlands (based on contributing institutions).